October 31, 2023
The Biden administration is aiming for a smooth transition as the rollout of COVID-19 treatments shifts to the private commercial market on Wednesday.
In a letter to drugmakers, distributors, pharmacies, and payors, the U.S. Department of Health and Human Services (HHS) asked for partnership during this transition period as the government moves away from its role as the primary supplier of COVID-19 treatments. The transition follows reports of uneven availability—and issues with insurance codes—that affected access to the updated COVID-19 vaccines following their debut on the commercial market last month
“As the federal government transitions away from distributing these products, access will primarily depend on the arrangements in the private commercial market among each of the particular drug manufacturers and private insurers,” Xavier Becerra, HHS secretary said in the letter. “We urge the drug manufacturers and private insurers to work together to ensure access to these lifesaving medications.”
Here’s what you need to know:
COVID-19 hospitalizations (16,186) remained level for the week ending October 21, while emergency department visits declined 4.6 percent in that time. HAP continues to monitor the latest COVID-19 public health developments and provide updates to members and the general public.
Becerra’s letter to the medical community is available online.
Tags: Public Health | COVID-19
Click on topic below for category-specific news articles.
Related Links